Bicycle Therapeutics Presents Data on EphA2-Targeted Therapies at AACR 2026
Event summary
- Bicycle Therapeutics will present five abstracts, including an oral presentation, at the AACR Annual Meeting 2026 in San Diego, April 17-22.
- The oral presentation focuses on preclinical assessment of BT5528 (nuzefatide pevedotin) in head and neck squamous cell carcinoma (HNSCC) models.
- Data will also be presented on a Phase 1/2 study combining BT5528 with nivolumab in patients with advanced solid tumors.
- Research includes preclinical assessment of BT5528 in pancreatic ductal adenocarcinoma (PDAC) models and development of a PET imaging agent targeting EphA2.
The big picture
Bicycle Therapeutics' focus on undruggable targets like EphA2 represents a strategic bet on innovative therapeutic modalities. The AACR presentations provide a critical data update on the progress of nuzefatide pevedotin and other pipeline candidates, which will influence investor sentiment and the company's ability to secure further partnerships or funding. The combination therapy with nivolumab highlights the increasing trend of immuno-oncology approaches in cancer treatment.
What we're watching
- Clinical Efficacy
- The Phase 1/2 data presented on BT5528 in combination with nivolumab will be crucial in determining the viability of this therapeutic approach and its potential to overcome resistance mechanisms in solid tumors.
- Target Validation
- The data on EphA2 expression across different cancer subtypes will inform the company's strategy for patient selection and potentially expand the applicability of Bicycle’s EphA2-targeting therapies.
- Imaging Potential
- The development of a PET imaging agent for EphA2 will likely influence the company’s ability to identify and stratify patients for clinical trials, potentially accelerating drug development timelines.
Related topics